JSB Market Research: EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

Page 1

JSB Market reSearch: epicaSt report: renal cell carcinoMa epideMiology ForecaSt to 2023 On 3rd Sept. 2014

Summary Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. The condition is asymptomatic in its initial stages, and as a result, people with RCC are often in the advanced stages of the disease by the time it is discovered. The initial symptoms of RCC often include blood in the urine, flank pain, a mass in the abdomen or flank, weight loss, fever, hypertension, night sweats, and a general feeling of being unwell. Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/


Kidney cancer is among the 10 most frequently occurring cancers in Western countries. GlobalData epidemiologists forecast that there were 186,179 incident cases of RCC in the 8MM in 2013, and the number of incident cases will grow 6.25% over the next decade to 302,449 incident cases. In 2013, there were 593,228 prevalent cases of RCC in the 8MM. Each of the 8MM will see an increase in prevalent cases over the 10-year forecast period. This forecast is supported by age- and sex-specific data for the incidence. The oneto five-year relative survival data, which were used for the five-year diagnosed prevalent cases forecast, are supported by country-specific, population-based studies that are nationally representative of the entire population in the respective markets. Additionally, in each of the 8MM, the analysis is strengthened by the use of a consistent methodology for the diagnosed incident cases forecast, using regression techniques, and is based on 15 years of country-specific historical data points pertaining to the age- and sex-specific diagnosed incidence of RCC. Scope • The Renal Cell Carcinoma (RCC) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for RCC in the eight major markets 8MM (US, France, Germany, Italy, Spain, UK, Japan, and urban China). It includes a 10-year epidemiological forecast for the diagnosed incident cases of RCC segmented by sex and age (in five-year age groups beginning at 20 years and ending at 85 years and older). • GlobalData epidemiologists also forecast the five-year diagnosed prevalent cases of RCC in the 8MM. Additionally, the report provides the RCC diagnosed incident cases, segmented by the stage at diagnosis, for the 8MM. • The RCC epidemiology report is written and developed by Masters- and PhD-level epidemiologists. • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM. Reasons to buy • Develop business strategies by understanding the trends shaping and driving the global RCC market. • Quantify patient populations in the global RCC market to improve product design, pricing, and launch plans. Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/


• Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for RCC therapeutics in each of the markets covered. Table of Contents: 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Catalyst 2.2 Upcoming Related Reports 3 Epidemiology 3.1 Disease Background 3.2 Risk Factors and Comorbidities 3.3 Global Trends 3.3.1 Incidence 3.3.2 Survival Rates for RCC - 8MM 3.4 Forecast Methodology 3.4.1 Sources Used 3.4.2 Sources Not Used 3.4.3 Forecast Assumptions and Methods, RCC Diagnosed Incident Cases 3.4.4 Forecast Assumptions and Methods, RCC Five-Year Diagnosed Prevalent Cases 3.4.5 Forecast Assumptions and Methods, RCC Clinical Stage at Diagnosis 3.5 Epidemiological Forecast for RCC (2013-2023) 3.5.1 Diagnosed Incident Cases of RCC 3.5.2 Age-Specific Diagnosed Incident Cases of RCC 3.5.3 Sex-Specific Diagnosed Incident Cases of RCC 3.5.4 Age-Standardized Diagnosed Incidence of RCC 3.5.5 Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis 3.5.6 Five-Year Diagnosed Prevalent Cases of RCC 3.6 Discussion 3.6.1 Epidemiological Forecast Insight Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/


3.6.2 Limitations of the Analysis 3.6.3 Strengths of the Analysis 4 Appendix 4.1 Bibliography 4.2 About the Authors 4.2.1 Epidemiologists 4.2.2 Reviewers 4.2.3 Acting Director of Epidemiology 4.2.4 Global Head of Healthcare 4.3 About GlobalData 4.4 About EpiCast 4.5 Disclaimer List of Tables Table 1: RCC Clinical Stages at Diagnosis Table 2: Risk Factors and Comorbidities for RCC Table 3: Trends in the Age-Adjusted Incidence of Kidney Cancers in the US, Ages =20 Years, 1993-2007 Table 4: Trends in the Age-Adjusted Incidence of Kidney Cancers in the 5EU, Ages =20 Years, 1993-2007 Table 5: Trends in the Age-Adjusted Incidence of Kidney Cancers in Japan, Ages =20 Years, 1993-2007 Table 6: Trends in the Age-Adjusted Incidence of Kidney Cancers in Urban China, Ages =20 Years, 1993-2007 Table 7: Trends in the Five-Year Relative Survival (%) of Kidney Cancers in the 8MM, Both Sexes, 1993-2009 Table 8: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Incident Cases Table 9: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Five-Year Prevalent Cases Table 10: 8MM, Sources of Epidemiological Data Used for the Segmentation of RCC Incident Cases by Clinical Stage at Diagnosis 1.1

Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/


Table 11: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages =20 Years, N, 2013-2023 Table 12: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N (Row %), 2013 Table 13: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages =20 Years, N (Row %), 2013 Table 14: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages =20 Years, N, 2013-2023

1.2 List of Figures Figure 1: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages =20 Years, N, 2013-2023 Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N, 2013 Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages =20 Years, N, 2013 Figure 4: 8MM, Age-Standardized Diagnosed Incidence of RCC (Cases per 100,000 Population), Ages =20 Years, by Sex, 2013 Figure 5: 8MM, Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis, Ages =20 Years, N, 2013 Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages =20 Years, N, 2013-2023 Related reports: Avaxia Biologics, Inc. - Product Pipeline Review - 2014 Affimed Therapeutics AG - Product Pipeline Review - 2014 Healthcare and Medical Market Research

Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/


About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is one-stop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience. To know more on EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

http://www.jsbmarketresearch.com/healthcare-medical/rEpiCast-Report-Renal-Cell-Carcinoma-Epidemiology-Forecast-to2023-123268

Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.